- Open Access
Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Multidisciplinary Respiratory Medicine volume 12, Article number: 17 (2017)
After publication of the Review article  it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide (pag 5) must be corrected as follows: “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat® at a dose of 5 μg once (delivered in two inhalation of 2.5 μg each) to patients with asthma, which was also approved in more than 50 countries, including Japan. In September 2015 the Food and Drug Administration confirmed the same indication, but with a dosage of 2.5 μg once daily (delivered in two inhalation of 1.25 μg each); the latter being extended for patients aged 6 and older since 16th February 2017.”
Radovanovic D, Santus P, Blasi F, Mantero M. The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscipl Respir Med. 2017;12:12. doi:10.1186/s40248-017-0094-3.
The online version of the original article can be found under doi:10.1186/s40248-017-0094-3.
About this article
Cite this article
Radovanovic, D., Santus, P., Blasi, F. et al. Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med 12, 17 (2017). https://doi.org/10.1186/s40248-017-0099-y